Company news: IMS Health, Havas Drive, Healthline Networks

Share this article:
IMS Health launched the IMS Institite for Healthcare Informatics, a bigthink initiative focusing on the use of medical information globally, the future global role of biopharmas, the role of innovation in health system products, processes and delivery systems, and advancement of healthcare agendas in developing nations.

Family practitioners are consistently the physicians most targeted by industry emails, but specialty physicians are more likely to open and click, a survey by Cegedim's SK&A unit found. In 2010, around 17% of all emails targeted family practitioners, but the highest open rates were for trauma surgeons (13.4%), hepatologists (13.2%) and dermatopathologists (11.1%).

Healthline Networks added several publishing partners to its media network, including Ask.com, DoctorOz.com, DailyStrength, DailyRx, Inspire and the Forward Health group, (Women's Health Base, Men's Health Base, All-Allergines.com and Good Cholesterol Count.com). The San Francisco-based firm claims a potential reach of 43 million unique visitors each month.

Havas Drive launched a unit offering “patient-centric services geared toward persons with disabilities and those undergoing rehabilitative therapies.” The new unit will offer strategic and technological products – including tablets, gaming consoles, haptic interfaces, virtual prosthetics, adaptive therapies, text-to-speech functionality and Second Life – serving populations with low vision, blindness, autism, degermative illnesses, behavioral disorders, cognitive difficulty and the hearing impaired.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.